Tifei Xu

机构：Chinese Academy of Sciences, Shanghai Institute of Materia Medica

发表论文 9 篇 · 总被引 120 次 · h-index 6

代表论文

• Discovery of novel dual functional agent as PPARγ agonist and 11β-HSD1 inhibitor for the treatment of diabetes (2009 · Bioorganic & Medicinal Chemistry · 被引 29)
• Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3 (2018 · Frontiers in Pharmacology · 被引 26)
• Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists (2023 · Journal of Medicinal Chemistry · 被引 18)
• SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice (2021 · Acta Pharmacologica Sinica · 被引 16)
• Coronarin A modulated hepatic glycogen synthesis and gluconeogenesis via inhibiting mTORC1/S6K1 signaling and ameliorated glucose homeostasis of diabetic mice (2022 · Acta Pharmacologica Sinica · 被引 12)
• Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats (2024 · European Journal of Medicinal Chemistry · 被引 8)